AGM 25th November 2016

Version: 160829PH Confidential

sementis™

Disclaimer

We believe that the information in this presentation is correct and any opinions and conclusions are reasonably held or made, based on the information available at the time of its compilation, but no representation or warranty, either expressed
or implied, is made or provided as to accuracy, reliability or completeness of any statement made in this presentation. Sementis Limited does not accept any liability for any loss or damage arising out of the use of all or any part of this presentation.

This presentation has been prepared without taking into account the objectives, financial situation or needs of any particular individual.

Board and Management

Maurice O'Shannassy

» Non-Executive Chairman

Maurice spent 25 years in the financial services industry in Australia and overseas. He currently holds a number of directorships in a variety of industries and not for profit organisations.

Jane Ryan PhD

» CEO Elect

Jane has many years of international experience in the pharmaceutical and biotechnology industry where she has managed research and development programs, as well as having key roles in business development and alliance management. She successfully negotiated a $231M US government contract with BARDA to support product development in the infectious diseases field. As Vice President of Product Development and Strategic Marketing at Biota she oversaw, clinical, regulatory, manufacturing, toxicology, saftey and market access groups

Tom Quirk MSc DPhil MA SMP

» Non-Executive Director

Tom has interests in venture capital, investment management and business advisory and brings the experience of many biotech start-ups (including Biota and Peptech), most recently as Chairman of Virax Holdings.

Paul Howley PhD

» Chief Scientist, Board Director, and Co-Founder

Paul's scientific background is in the field of molecular virology, specialising in viral vector systems and vaccinology. Paul is the inventor of the Sementis SCV platform vaccine delivery technology and of a number of vaccines in development. He directs and manages the vaccine development programs for Sementis, utilising his extensive knowledge, experience and networks in the areas of antigen design and discovery, proof of concept studies in animal models, GLP preclinical and toxicology studies, process development and cGMP manufacturing, regulatory affairs and first in man studies concerning live viral vectored vaccines.

Sementis propriety SCV platform technology



Live virus vector derived by totally attenuating a strain of vaccinia virus

Enables development of new vaccines in the field of infectious diseases, allergies and oncology

Principles of the SCV approach

SCV platform is a totally attenuated vaccinia virus vector plus rescue cell line

Genetic engineered so no progeny but maintains genome replication, gene amplification and late gene expression

Can not replicate in man but delivers antigens to the immune system to stimulate the desired response

"Rescue" cell line is a genetically engineered CHO cell line which allows complete multiplication of the active virus

Significant manufacturing improvements

Sementis Mission



Sementis Strategy Optimizing the SCV technology

Core Technology

- Sementis Copenhagen Victor (SCV)
- novel production method (CHO rescue cell)

Allergies

- allergies offer large markets
- high product prices

Peanut | **Cat**

Develop in-house

Expanded pipeline

- license to others for milestone **and** royalties payments
- modest royalties
- potential products include

Cancer

license to others

Mosquito borne diseases

- lower price products
- potential for government NGO to fund
- potential products include

Chikungunya | **Zika**

Research to date being prepared for partnership

Sementis Mission



Advantages of the CHO-rescue cell line

Target Profile
Yields & Scale up ability

Fast rate of growth

High cell density culturing

Suspension culture in BioReactors

Growth in chemically defined protein-free media

Improved yield over comparable methods

Savings in costs of goods

Laboratory Research Activities

Demonstrate that un-optimised CHO- rescue cell line produces comparable yields to other methods of viral-vector manufacture in protein free media

Proof of concept for the CHO-rescue cell approach

Scale Up Development Activities: CMO

Develop detailed Technology Development Plan

Continue development of GMP CHO-rescue cell line

Continue manufacture license discussions with interested parties

Demonstrate and develop knowhow and IP around the scale up methods of SCV vaccine

Sementis Mission



Allergy vaccines: peanut allergy

Target Product Profile

Immunomodulatory

Shift immune response to peanut antigen from allergic TH-2 to nonallergic TH-1

Short course with long lasting effects

Effectively a cure

No enhancement of pre-existing disease

Non replicating

Laboratory Research

Data demonstrates shift from TH-2 to TH-1 in mice and allergic individual ex vivo

No enhancement of pre-existing disease in mice

Repeat mice and human ex vivo studies to including dose response

Non-replicating

Future Activities

Aim to develop in house to proof of concept Phase I/IIa to maximize value to shareholders

Identify HNW with an interest in peanut allergy

Continue work on any potential grants or non-diluting funding

With funds complete pre-clinical work and GMP manufacture

Ex vivo immunized cells from an allergic individual



DC_{SCV105}: SCV105 infected dendritic cells (vector only control); **DC_{PNE}**: dendritic cells mixed with peanut protein extract; **DC_{SCV204}**: SCV204 infected dendritic cells (Major plus Minor allergen vaccine)

Sementis Mission



Witty CEO GSK:
Big Pharma can help the poor and still make money

http://fortune.com/2016/11/02/glaxosmithkline-witty-brainstorm-health/

For GSK, it means making at least some profit in every single market, no matter how small that profit may be. Some investors might balk at that strategy and demand a greater return. But there's also a compelling logic to the idea.

"We literally rank the world by [gross national income] per capita" when it comes to certain drugs such as vaccines, said Witty. Glaxo then applies a tiered pricing strategy based on economic need. And on the flip side, organizations like Gavi, the massive global public-private vaccine partnership, ensure a certain amount of purchases (albeit for a significantly reduced price) as long as companies commit to providing a reliable stream of treatments.

It's a low-margin, high-volume proposition. But it's one that Witty deeply believes is integral to serving the world's "other six billion" who don't live in middle-to-high income nations while hewing to the profit motive. He points to successes such as the part GlaxoSmithKline has played in reducing childhood mortality in sub-Saharan Africa by investing in an expensive vaccine manufacturing plant in Singapore.

Expanded opportunities for partnering: Chikungunya and Zika

sementis

Target Product Profile

Single dose option with long lasting immunity

Safe including non replicating

No enhancement of pre-existing disease

Prophylactic protection against infection

Protective against persistent infection

Laboratory Research

Proof of concept for the Target Product Profile for Chikungunya

Work ongoing for Zika combined **Zika and Chikungunya combined** vaccines **to protect both diseases**

Partnering Activities

Data package on Chikungunya vaccine currently being review by potential business partners

Identify potential grant partners

Demonstrate scale up of SCV vaccine through partnering

Continue work on combined vaccine through partnering and grants

Chikungunya vaccine

SCV-CHIK vaccine induced foot swelling (arthritis) after Chikungunya virus challenge

Immunisation with SCV305 at 106 pfu/mouse was fully protective against Chikungunya virus induced foot swelling



Fundraising

Grants

- University South Australia

  ARC-Linkage: $362,000 for a 3 year period; Post-Doc salary and consumable costs

  Science and Industry Endowment Fund STEM+ Business Industrial Research Fellowship Award: $300,00 for a 3 year period; Post-Doc salary and consumable costs

- QIMR Berghofer Medical Research Institute

  Advance Queensland Research Fellowship Award; $300,00 for a 3 year period Post-Doc salary and consumable costs commencing 2017

- R&D tax concession

  FY2016 $951,434

Fundraising

- Short term
  - High Net Worth (2-5M)
  - Specialist funds
  - R&D tax concession
  - Ongoing grants
- Medium term
  - Licensing
  - Biotech Investment funds (approx 15M)
  - Grants
- Longer term
  - Trade scale
  - Listing

Contact

» **Jane Ryan** | CEO

For further information please call +61 419 541 623
or email jane.ryan@sementis.com.au

sementis™